SELLAS Life Sciences To Present Final Data From Phase 1/2 Study Of Galinpepimut-S In Combination With Keytruda In Patients With WT1+ Platinum-Resistant Advanced Ovarian Cancer At The International Gynecologic Cancer Society 2023 Annual Global Meeting
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) will present the final data from the Phase 1/2 clinical trial of galinpepimut-S (GPS) in combination with pembrolizumab (Keytruda®) in Wilms' tumor-1 (WT1)-positive platinum-resistant ovarian cancer at the 2023 International Gynecologic Cancer Society (IGCS) Annual Global Meeting. The study was sponsored by SELLAS and conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. Based on the data, SELLAS plans to submit a full-length manuscript to a peer-reviewed journal in the first half of 2024.
October 17, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences is set to present the final data from their Phase 1/2 clinical trial of galinpepimut-S in combination with Keytruda in patients with WT1+ platinum-resistant advanced ovarian cancer. This could potentially impact the company's stock positively if the results are favorable.
The presentation of the final data from the Phase 1/2 clinical trial could potentially have a positive impact on SELLAS Life Sciences' stock. If the results are favorable, it could increase investor confidence in the company's ability to develop effective treatments, which could drive up the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100